secwatch.observer — SEC 8-K summary
======================================

Issuer:     TherapeuticsMD, Inc. (TXMD)
CIK:        0000025743
Form:       8-K
Filed at:   2023-06-28T23:59:59+00:00
Accession:  0001193125-23-176709
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

TherapeuticsMD stockholders approve charter amendment and private placement at 2023 annual meeting
--------------------------------------------------------------------------------

- Elected all four director nominees (Thompson, Collins, Naughton, Roberts) with over 4 million 'for' votes each.
- Approved charter amendment to increase authorized common shares from 12 million to 32 million with 5,431,781 votes for.
- Approved private placement of up to 5 million shares to Rubric Capital Management with 4,178,998 votes for.
- Non-binding advisory vote on named executive officer compensation passed with 4,007,930 votes for.
- Ratified Grant Thornton LLP as independent auditor for fiscal 2023 with 5,875,689 votes for.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/25743/000119312523176709/0001193125-23-176709-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/25743/000119312523176709/d499064d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-176709

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer